Earlier this year, the StemCells Inc. completed enrollment in an open-label Phase I/II clinical trial in thoracic SCI using its proprietary HuCNS-SC® platform of human neural stem cells to treat 8 patients. Half of the patients transplanted had significant post-transplant gains in sensory function. Based upon the strength of the interim data from this study, the Company made the decision to move forward with the first in human clinical trial to assess the efficacy of stem cell transplants for the treatment of cervical SCI.
StemCells, Inc. begins Phase II clinical trial in cervical spinal cord injury
Skip back to main navigation